You are here

Neuroscience Pipeline

Pfizer's mission is to deliver medicines that make a real difference in quality of life for patients with neuroscience- and pain-related conditions. Scientists in our research and development (R&D) programs are committed to speeding the delivery of new treatments. We pledge to maintain the safety of patients who take part in our trials and to uphold the highest ethical standards in all of our research initiatives.

On this page, you will find more information about our pipeline, which investigational therapies are under development, and in which stages.

 

Neuroscience & Pain Pipeline as of

  • Discovery Projects
  • Phase 1
    5
  • Phase 2
    2
  • Phase 3
    1
  • Registration
    1
  • Total9
 
Compound Name
Indication
Phase
Submission Type
Compound Typesort descending
Lyrica
Therapeutic Area:
Neuroscience
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Alpha-2 Delta Ligand
Go to clinical trial
CR (once a day dosing) Registration Product Enhancement Small Molecule
PF-04958242
Therapeutic Area:
Neuroscience
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
AMPA Ion Channel
Go to clinical trial
Schizophrenia Phase 1 New Molecular Entity Small Molecule
PF-05251749
Therapeutic Area:
Neuroscience
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Combination: Casein kinase I delta/epsilon
Go to clinical trial
Alzheimer's Disease Phase 1 New Molecular Entity Small Molecule
PF-06372865
Therapeutic Area:
Neuroscience
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
GABA A Receptor Agonist
Go to clinical trial
Epilepsy Phase 2 New Molecular Entity Small Molecule
PF-06648671
Therapeutic Area:
Neuroscience
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Gamma secretase complex Modulator
Go to clinical trial
Alzheimer's Disease Phase 1 New Molecular Entity Small Molecule
PF-06649751
Therapeutic Area:
Neuroscience
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Dopamine 1 activator
Go to clinical trial
Parkinson's Disease Phase 2 New Molecular Entity Small Molecule
PF-06669571
Therapeutic Area:
Neuroscience
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Dopamine 1 activator
Go to clinical trial
Cognitive Disorder Phase 1 New Molecular Entity Small Molecule
PF-06751979
Therapeutic Area:
Neuroscience
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
Enzyme Inhibitor
Go to clinical trial
Alzheimer's Disease Phase 1 New Molecular Entity Small Molecule
tanezumab
Therapeutic Area:
Neuroscience
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Nerve Growth Factor Inhibitor
Go to clinical trial
OA Signs and Symptoms (FAST TRACK), Chronic Low Back Pain (FAST TRACK), Cancer Pain (Biologic) Phase 3 New Molecular Entity Biologic